NEW YORK (GenomeWeb) – Myriad Genetics is gearing up for a major commercialization push for BRACAnalysis CDx after gaining regulatory approval in the metastatic breast cancer setting and is working to expand reimbursement for the Vectra DA and GeneSight tests.

The company provided an update on its effort to grow adoption of its products during a call to discuss second quarter financial results of its fiscal year 2018. During that period, molecular diagnostics revenues declined 3 percent to $179.2 million, from $183.9 million a year ago.